Unicef

WHO announces MVA-BN vaccine as the first mpox vaccine to be added to its prequalification list, manufactured by Danish lab Bavarian Nordic A/S. This approval aims to facilitate timely access, reduce transmission, and help contain outbreaks. The vaccine is administered in two doses, 4 weeks apart, for individuals over 18 years old.

WHO approves first mpox vaccine, MVA-BN from Bavarian Nordic, to aid Africa's outbreak; vaccine prequalification aims to accelerate access and reduce transmission.

WHO approves MVA-BN vaccine as first mpox vaccine for prequalification, aiming to facilitate timely access and reduce transmission. The vaccine, administered in 2 doses 4 weeks apart, can be stored at 2–8°C for up to 8 weeks and is recommended for high-risk individuals, including 'off-label' use in children and pregnant women. Single-dose use is advised in supply-constrained situations, with estimated 76% effectiveness pre-exposure and 82% with 2 doses.

The MVA-BN vaccine from Bavarian Nordic, prequalified by WHO, is approved for adults in Europe and the U.S. WHO's approval aims to accelerate access to reduce mpox transmission. The vaccine, 82% effective with two doses, can be used in special cases like infants and immunocompromised individuals. WHO's prequalification aids procurement and regulatory approval globally.

Bavarian Nordic’s MVA-BN vaccine is the first mpox vaccine to receive WHO pre-qualification, enabling global use. WHO recommends single doses in supply-constrained situations and 'off label' use for children and immuno-compromised individuals. The vaccine is currently approved for adults, with ongoing studies for younger age groups. Bavarian Nordic aims to produce two million doses by the end of 2024.

WHO authorized an mpox vaccine, crucial for combating outbreaks in Africa, particularly in the Democratic Republic of the Congo. The vaccine, produced by Bavarian Nordic, is limited to a single manufacturer and primarily authorized for adults. Wealthy countries have already approved it, and donations are planned, but Africa CDC estimates 10 million vaccines are needed. Mpox, milder than smallpox, causes fever, chills, and body aches, with severe cases developing lesions.

WHO announced MVA-BN vaccine as the first mpox vaccine to be added to its prequalification list, facilitating increased access to reduce transmission. The vaccine, administered in two doses four weeks apart to those over 18, can be stored at 2-8°C for up to eight weeks. This prequalification aims to accelerate procurement and rollout, ensuring equitable access and saving lives.

WHO adds MVA-BN vaccine to prequalification list for Mpox, aiming to increase access and contain outbreaks. The vaccine, administered in 2 doses, can be kept at 2–8°C for up to 8 weeks and is recommended for high-risk individuals. WHO emphasizes the need for equitable access and data collection on vaccine safety and effectiveness.